Neurostimulation for Parkinson disease

JAMA

Volumn 301, Issue 1, 2009, Pages 104-105

  Deuschl, Günther ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

BRAIN CORTEX; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; EDITORIAL; EMBRYONIC STEM CELL; GLOBUS PALLIDUS; HUMAN; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PATIENT MOBILITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; THERAPY EFFECT; TREATMENT RESPONSE; VERBAL MEMORY; WORKING MEMORY; NOTE;

DEEP BRAIN STIMULATION; HUMANS; PARKINSON DISEASE;

EID: 58149375888     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.938     Document Type: Editorial

References (16)

1. Birkmayer W, Der Hornykiewicz O. L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr. 1961;73:787-788.
2. Lang AE, Lozano AM. Parkinson's disease. N Engl J Med. 1998;339(16):1130-1143.
3. Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol. 1994;35(2):172-180.
4. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344(10):710-719.
5. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54(3):403-414.
6. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008;7(5):400-408.
7. Ceregene announces clinical data from phase 2 clinical trial of CERE-120 for Parkinson's disease [press-release]. http://www.ceregene.com/press-12608. asp. Posted November 26, 2008. Accessed December 12, 2008.
8. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990;13(7):266-271.
9. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990;249(4975):1436-1438.
10. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med. 2000;342(7):461-468.
11. Weaver F, Follett K, Stern M, et al; for the CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73.
12. Deuschl G, Schade-Brittinger C, Krack P, et al; German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.
13. Voges J, Hilker R, Botzel K, et al. Thirty days complication rate following surgery performed for deep-brain-stimulation. Mov Disord. 2007;22(10):1486-1489.
14. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain. 2008;131(pt 10):2720-2728.
15. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol. 2008;7(7):605-614.
16. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain. 2005;128(pt 10):2240-2249.